Navigation Links
Creabilis Raises €15M ($20M) in Series B Fundraising Round
Date:10/4/2011

LUXEMBOURG, October 4, 2011 /PRNewswire/ --

Funds to Advance Development of Creabilis' First-in-Class Products

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures. Existing investors Neomed and Sofinnova Partners, as well as private Italian investors, joined the round. The new funds will be used to finance the development of the company's first-in-class treatments, including its lead product CT327 to the end of phase II.

CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis' Low Systemic Exposure (LSE) technology. Positive efficacy of CT327 has been seen in two Phase IIa studies, in both psoriasis and atopic dermatitis, in which CT327 was well tolerated and demonstrated a good safety profile. CT327 is also in development for the treatment of pain, with proof-of-concept trials currently underway.

The company's pipeline also includes CT637, a new approach to the treatment of significant inflammatory and autoimmune conditions and CT340, a potent TrkA kinase inhibitor that has therapeutic potential in a broad range of inflammatory conditions. CT637 and CT340 are anticipated to reach Investigational New Drug application (IND) stage of development in early 2012.

Dr Eliot Forster CEO of Creabilis said: "This new funding reflects the medical importance and significant commercial potential of our drugs pipeline. In Abbott Biotech Ventures, we have added another leading life science investor into the Company. Their involvement, and the ongoing support of our existing investors, demonstrates their confidence in the Company and in our ability to drive our projects forward."

For further information please contact:


Creabilis
Eliot Forster
eforster@creabilis-sa.com
Creabilis SA
5 rue Jean Monnet L-2810 LUXEMBOURG
                   
Citigate Dewe Rogerson
Chris Gardner or Nina Enegren
Tel: +44(0)20-7282-1050
E-mail: nina.enegren@citigatedr.co.uk

About Creabilis SA

Creabilis is a clinical-stage European biotechnology company creating innovative new drugs to tackle unmet medical needs in dermatology and inflammatory diseases. Bringing together world class drug development capabilities and a rich scientific heritage, Creabilis is uniquely positioned to transform the treatment of its target diseases.

Creabilis' lead product is CT327 a novel topically applied TrkA kinase inhibitor developed using the Company's Low Systemic Exposure (LSE) technology. CT327 is currently in Phase II clinical trials in psoriasis and atopic dermatitis and is undergoing proof-of-concept studies in pain. CT340 is a potent TrkA kinase inhibitor under development for the treatment of conditions in which TrkA kinase inhibition is indicated, including inflammatory arthritis, and pain. The Creabilis portfolio also includes CT637, a new approach to the treatment of significant inflammatory conditions, such as rheumatoid arthritis. Earlier-stage projects include a number of highly promising candidates for dermatological and wider indications.

Creabilis is backed by some of Europe's most highly respected life sciences investors including Sofinnova Partners, Neomed and Abbott Biotech Ventures.

For more information, please visit:  http://www.creabilis-sa.com



'/>"/>
SOURCE Creabilis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Creabilis Appoints Dr David Roblin as Chief Medical Officer
2. Creabilis Expands Senior Management Team
3. Bacon Eating Contest Raises Money for American Heart Association
4. Proteolix Raises $79 Million in Series C Financing
5. Yongye Biotechnology International Raises $9.4 Million in Private Placement
6. MacroGenics Raises $25M in Series D-2 Financing
7. China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income
8. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
9. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65
10. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
11. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
(Date:6/23/2016)... NEWPORT BEACH, Calif. , June 23, 2016 /PRNewswire/ ... offering new biological discoveries to the medical community, has ... and co-founder Matthew Nunez . "We ... provide us with the capital we need to meet ... funding will essentially provide us the runway to complete ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):